Literature DB >> 24237985

HUS and TTP in Children.

Howard Trachtman1.   

Abstract

This review describes the epidemiology, pathophysiology, presentation, clinical causes, treatment, and long-term prognosis of pediatric patients who present with thrombotic microangiopathy. The focus is on hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, the most common phenotypes of thrombotic microangiopathy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative pathway of complement (APC); Hemolytic uremic syndrome (HUS); Shiga toxin (Stx); Thrombotic microangiopathy (TMA); Thrombotic thrombocytopenic purpura (TTP)

Mesh：

Year:  2013        PMID： 24237985      PMCID： PMC3972058          DOI： 10.1016/j.pcl.2013.08.007

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN： 0031-3955            Impact factor:   3.278


  52 in total

Review 1.  Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.

Authors:  Tania N Petruzziello-Pellegrini; Philip A Marsden
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

2.  Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins.

Authors:  Phillip I Tarr; Diana Karpman
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

Review 3.  Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.

Authors:  William F Clark
Journal:  Semin Dial       Date:  2012-02-07       Impact factor: 3.455

Review 4.  Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.

Authors:  Kent Chapman; Michael Seldon; Ross Richards
Journal:  Semin Thromb Hemost       Date:  2012-02-07       Impact factor: 4.180

5.  Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Haifeng M Wu; Andrea Cairo; Giorgio Bentivoglio; Flora Peyvandi
Journal:  Blood Cells Mol Dis       Date:  2012-09-11       Impact factor: 3.039

6.  An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.

Authors:  Sebastian Loos; Thurid Ahlenstiel; Brigitta Kranz; Hagen Staude; Lars Pape; Christoph Härtel; Udo Vester; Laura Buchtala; Kerstin Benz; Bernd Hoppe; Ortraud Beringer; Martin Krause; Dominik Müller; Martin Pohl; Johanna Lemke; Georg Hillebrand; Martin Kreuzer; Jens König; Marianne Wigger; Martin Konrad; Dieter Haffner; Jun Oh; Markus J Kemper
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

Review 7.  Unwinding the von Willebrand factor strings puzzle.

Authors:  Karen De Ceunynck; Simon F De Meyer; Karen Vanhoorelbeke
Journal:  Blood       Date:  2012-10-23       Impact factor: 22.113

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 9.  Renal and neurological involvement in typical Shiga toxin-associated HUS.

Authors:  Howard Trachtman; Catherine Austin; Maria Lewinski; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 10.  Defective complement inhibitory function predisposes to renal disease.

Authors:  Anuja Java; John Atkinson; Jane Salmon
Journal:  Annu Rev Med       Date:  2012-11-01       Impact factor: 13.739
View more
  8 in total

1.  CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).

Authors:  Caroline Caillaud; Ariane Zaloszyc; Christoph Licht; Valérie Pichault; Véronique Frémeaux-Bacchi; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 2.  Hemolytic uremic syndrome: toxins, vessels, and inflammation.

Authors:  Victoria Cheung; Howard Trachtman
Journal:  Front Med (Lausanne)       Date:  2014-11-04

3.  Norovirus: a novel etiologic agent in hemolytic uremic syndrome in an infant.

Authors:  Ghadi Abu Daher; Bilal Aoun; Fatima Jaafar; Sarah Khafaja; Sami Sanjad
Journal:  BMC Nephrol       Date:  2019-07-05       Impact factor: 2.388

Review 4.  An ADAMTS13 mutation that causes hereditary thrombotic thrombocytopenic purpura: a case report and literature review.

Authors:  Pengzhu Li; Jie Jiang; Qiong Xi; Zuocheng Yang
Journal:  BMC Med Genomics       Date:  2021-10-26       Impact factor: 3.063

Review 5.  Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.

Authors:  Marija Malgaj Vrečko; Andreja Aleš Rigler; Željka Večerić-Haler
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

6.  Thrombocytopenia-associated multiorgan failure occurring in an infant at the onset of type 1 diabetes successfully treated with fresh frozen plasma.

Authors:  Revati Kumar; Brent McSharry; Peter Bradbeer; Esko Wiltshire; Craig Jefferies
Journal:  Clin Case Rep       Date:  2016-06-02

7.  Enterohaemorrhagic E. coli modulates an ARF6:Rab35 signaling axis to prevent recycling endosome maturation during infection.

Authors:  R Christopher D Furniss; Sabrina Slater; Gad Frankel; Abigail Clements
Journal:  J Mol Biol       Date:  2016-05-31       Impact factor: 5.469

Review 8.  Acquired thrombotic thrombocytopenia purpura associated with severe ADAMTS13 deficiency in a 3-year-old boy: a case report and review of the literature.

Authors:  Hamidah Alias; Woon Lee Yong; Farah Azima Abdul Muttlib; Ho Wai Koo; C-Khai Loh; Sie Chong Doris Lau; Hafiza Alauddin; Raja Zahratul Azma
Journal:  J Med Case Rep       Date:  2018-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.